Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors

The International Journal of Neuropsychopharmacology
Lina ChiuccarielloJeffrey H Meyer

Abstract

Monoamine oxidase inhibitors (MAOIs) are being developed for major depressive disorder, Alzheimer's, and Parkinson's Disease. Newer MAOIs have minimal sensitivity to tyramine, but a key limitation for optimizing their development is that standards for in vivo monoamine oxidase-A (MAO-A) occupancy in humans are not well established. The objectives were to determine the dose-occupancy relationship of moclobemide and the occupancy of phenelzine at typical clinical dosing. Major depressive episode (MDE) subjects underwent [(11)C]harmine positron emission tomography scanning prior to and following 6 weeks of treatment with moclobemide or phenelzine. Mean brain MAO-A occupancies were 74.23±8.32% for moclobemide at 300-600 mg daily (n = 11), 83.75±5.52% for moclobemide at 900-1200 mg daily (n = 9), and 86.82±6.89% for phenelzine at 45-60 mg daily (n = 4). The regional dose-occupancy relationship of moclobemide fit a hyperbolic function [F(x) = a(x/[b + x]); F(1,18) = 5.57 to 13.32, p = 0.002 to 0.03, mean 'a': 88.62±2.38%, mean 'b': 69.88±4.36 mg]. Multivariate analyses of variance showed significantly greater occupancy of phenelzine (45-60mg) and higher-dose moclobemide (900-1200 mg) compared to lower-dose moclobemide [300-600 mg; F(...Continue Reading

References

Mar 1, 1991·Journal of Affective Disorders·G B BakerR T Coutts
Jan 1, 1995·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·N A LassenP N Patsalos
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·J S FowlerA P Wolf
May 1, 1997·Nuclear Medicine and Biology·M BergströmB Långström
Nov 5, 1997·NeuroImage·J Ashburner, K Friston
Jun 1, 2000·Journal of Clinical Psychopharmacology·D M MagderS H Kennedy
Jan 4, 2001·The American Journal of Psychiatry·J H MeyerS H Kennedy
Aug 29, 2001·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·O MawlawiM Laruelle
Aug 5, 2003·Pharmacology, Biochemistry, and Behavior·M J SchwarzA D Lees
Jun 24, 2004·The Australian and New Zealand Journal of Psychiatry·Peter Ellis, UNKNOWN Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression
Aug 5, 2005·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Nathalie GinovartAlan A Wilson
Mar 23, 2006·Nature Reviews. Neuroscience·Moussa B H YoudimKeith F Tipton
May 27, 2006·The Journal of Biological Chemistry·Xiao-Ming OuJean C Shih
Jun 27, 2006·Psychiatry Research·Pablo RusjanShitij Kapur
Jul 11, 2006·Proceedings of the National Academy of Sciences of the United States of America·Xiao-Ming OuJean C Shih
Aug 30, 2007·Nature Neuroscience·Kerry J Ressler, Helen S Mayberg
Sep 22, 2007·Journal of Neurochemistry·Julia C FitzgeraldE Ellen Billett
Apr 9, 2008·Proceedings of the National Academy of Sciences of the United States of America·Se-Young SonTomitake Tsukihara
Aug 14, 2009·Journal of Affective Disorders·Raymond W LamUNKNOWN Canadian Network for Mood and Anxiety Treatments (CANMAT)
Aug 21, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joseph L Price, Wayne C Drevets
Sep 2, 2009·Neuropsychiatric Disease and Treatment·Yogesh Dwivedi
Sep 10, 2009·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Vincent J CunninghamRoger N Gunn
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joanna S FowlerKaren Apelskog-Torres
Nov 19, 2009·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Michel BottlaenderMarie-Claude Grégoire
May 5, 2010·Archives of General Psychiatry·Julia SacherJeffrey H Meyer
Jun 10, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Shakevia JohnsonXiao-Ming Ou
Oct 29, 2011·European Archives of Psychiatry and Clinical Neuroscience·Thomas C BaghaiUNKNOWN Section of Pharmacopsychiatry, World Psychiatric Association
Dec 13, 2012·Current Topics in Medicinal Chemistry·Matilde YáñezReyes Laguna
Oct 25, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lina ChiuccarielloJeffrey H Meyer

❮ Previous
Next ❯

Citations

Oct 30, 2016·Journal of Natural Products·Narayan D ChaurasiyaBabu L Tekwani
Jul 18, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Rona R Ramsay, Keith F Tipton
Mar 9, 2018·Journal of Neural Transmission·Rona R Ramsay, Alen Albreht
Oct 31, 2018·Journal of Neural Transmission·Andrew Holt
Jul 6, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Adjia HamadjidaPhilippe Huot
Aug 28, 2020·Neurodegenerative Disease Management·Philippe Huot
Mar 29, 2018·Current Medicinal Chemistry·Denis SarrouilheCatherine Dejean
Oct 3, 2018·Frontiers in Molecular Neuroscience·Yuki HiguchiIshwar S Parhar

❮ Previous
Next ❯

Methods Mentioned

BETA
pregnancy test

Software Mentioned

Sigmaplot
Lassen Plot
Phenomenome Discoveries
SPSS

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.